Fresenius Kabi USA receives AP status for Dexamethasone Sodium Phosphate ANDA209192
Fresenius Kabi USA's ANDA209192 for Dexamethasone Sodium Phosphate has received Abbreviated Approval (AP) status.
Asset
Fresenius
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The Abbreviated Approval (AP) status granted to Fresenius Kabi for Dexamethasone Sodium Phosphate signifies increased competition in the corticosteroid market. This could impact pricing and market share for existing products, necessitating strategic adjustments by other players in the market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for the launch date and market uptake of the generic product.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.